Roche, Novartis are revving up next-generation eye drugs, but are they true contenders?
admin 29th October 2018 Uncategorised 0Roche and Novartis are working hard on next-generation drugs for wet age-related macular degeneration, and they’re hoping to steal significant market share away from entrenched drugs like Regeneron’s Eylea. But analysts aren’t convinced the new candidates can do the job.
More: Roche, Novartis are revving up next-generation eye drugs, but are they true contenders?
Source: fierce